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Edited by Horst FeldmannAbstract Point mutations in mitochondrial (mt) tRNA genes
are associated with a variety of human mitochondrial diseases.
We have shown previously that mt tRNALeu(UUR) with a
MELAS A3243G mutation and mt tRNALys with a MERRF
A8344G mutation derived from HeLa background cybrid cells
are deﬁcient in normal taurine-containing modiﬁcations
[sm5(s2)U; 5-taurinomethyl-(2-thio)uridine] at the anticodon
wobble position in both cases. The wobble modiﬁcation deﬁ-
ciency results in defective translation. We report here wobble
modiﬁcation deﬁciencies of mutant mt tRNAs from cybrid cells
with diﬀerent nuclear backgrounds, as well as from patient tis-
sues. These ﬁndings demonstrate the generality of the wobble
modiﬁcation deﬁciency in mutant tRNAs in MELAS and
MERRF.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Mitochondrial DNA (mtDNA) mutations are responsible
for a wide spectrum of human diseases caused by mitochon-
drial dysfunction [1]. An A to G mutation either at nucleo-
tide position (np) 3243 in the tRNALeu(UUR) gene or at np
8344 in the tRNALys gene has been shown to be responsible
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doi:10.1016/j.febslet.2005.04.038and stroke-like episodes (MELAS) and myoclonus epilepsy
associated with ragged-red fibers (MERRF), respectively.
These mutations, which are responsible for two major sub-
groups of the mitochondrial encephalomyopathies [2–4], were
demonstrated to be the direct cause of reductions in oxygen
consumption and mitochondrial protein synthesis [1] using
a cybrid cell system in which mutant mtDNAs derived from
patients were intercellularly transferred into recipient cells
lacking mtDNA (q0 cells) [5]. Several cybrid cell lines have
been constructed with diﬀerent nuclear backgrounds, includ-
ing 143B osteosarcoma, HeLa and A549 lung carcinoma cells
[5–7].
We have previously shown that several disease-associated
mitochondrial tRNA gene mutations are associated with a lack
of taurine wobble base-modiﬁcation in the mutant tRNAs. In
HeLa cybrid cells homoplasmic for pathogenic mtDNA muta-
tions, the taurine-containing modiﬁed uridine (sm5U; 5-tauri-
nomethyluridine) [8], which normally occurs at the anticodon
wobble position of mt tRNALeu(UUR), remains unmodiﬁed in
mt tRNALeu(UUR) bearing either the A3243G or T3271C
MELAS mutation (Fig. 1) [9]. Similarly, the mt tRNALys with
the A8344G MERRF mutation also lacks normal taurine-
modiﬁcation (sm5s2U; 5-taurinomethyl-2-thiouridine) at the
wobble position (Fig. 1) [8,10]. It is known that uridine mod-
iﬁcation at the wobble position is responsible for precise and
eﬃcient codon recognition [11–13]. In the case of MERRF,
we previously showed that the mutant tRNALys lacking the
wobble modiﬁcation loses translational activity for both
AAA and AAG codons [14]. In the case of MELAS, we re-
cently reported that the mt tRNALeu(UUR) lacking the tau-
rine-modiﬁcation showed severely reduced UUG translation
but no decrease in UUA translation [15,16]. We thus con-
cluded that the UUG codon–speciﬁc translational defect of
the mutant mt tRNALeu(UUR) is the primary cause of MELAS
at the molecular level. This result could explain the defective
translation of UUG-rich genes, such as ND6, leading to com-
plex I deﬁciency as observed clinically in MELAS. These ﬁnd-
ings strongly suggest that lack of the wobble modiﬁcation is
the primary molecular pathogenesis causing these mitochon-
drial diseases. However, the possibility remains that theblished by Elsevier B.V. All rights reserved.
Fig. 1. Cloverleaf structure of human mitochondrial tRNALeu(UUR)
and tRNALys. The wobble modiﬁed uridines in the wild-type
tRNALeu(UUR) and tRNALys are 5-taurinomethyluridine (sm5U) and
5-taurinomethyl-2-thiouridine (sm5s2U), respectively [8]. The MELAS
andMERRF point mutations, A3243G in tRNALeu(UUR) and A8344G
in tRNALys, respectively, are shown. The U on a round black
background indicates the unmodiﬁed uridine present in the mutant
tRNAs. The other modiﬁed nucleosides were determined previously:
1-methyladenosine (m1A), N6-threoninocarbonyladenosine (t6A),
1-methylguanosine (m1G), 2-methylguanosine (m2G), pseudouridine
(W), ribothymidine (T) dihydrouridine (D), and 5-methylcytidine
(m5C) [9,10,35].
T. Yasukawa et al. / FEBS Letters 579 (2005) 2948–2952 2949wobble modiﬁcation deﬁciency depends on the nuclear back-
ground of cybrid cell lines and does not reﬂect the situation
in vivo, because behavior of mtDNA often depends upon the
nuclear background in cybrids [17,18].
To assess the generality of the modiﬁcation deﬁciency in mu-
tant tRNAs, we analyzed the mutant tRNAs in actual tissues
of MELAS and MERRF patients. Here, we describe the con-
ﬁrmation of the wobble modiﬁcation deﬁciency in mutant
tRNAs from cybrid cells with diﬀerent nuclear backgrounds,
as well as from patient tissues.2. Materials and methods
2.1. Cell lines and cell culture
An A549 lung carcinoma cybrid containing 99% mtDNA with the
A3243G mutation in the tRNALeu(UUR) gene [18] was cultured in Dul-
becco-modiﬁed Eagles medium (DMEM) with 10% fetal bovine serum
and uridine at 50 lg/mL. The 143B osteosarcoma cybrid lines used
were: R1–C3, carrying predominantly the A8344G mutation;
R2-1, the wild-type counterpart of R1–C3; 43B, carrying predomi-
nantly the A3243G mutation; 94I, the wild-type counterpart of 43B
[19,20]. The 143B cybrids were kindly provided by Dr. Attardi and
Dr. Chomyn (California Institute of Technology, Pasadena, CA) and
were cultured in DMEM with 10% fetal bovine serum.2.2. Patient tissues
A patient died at the age of 22 in 1971 at Niigata University Hospi-
tal, Niigata, Japan and was reported as the ﬁrst case of MERRF in
1980 [21]. The specimen from the autopsied liver (15 mg) of the
MERRF patient contained 76% mutant and 24% wild-type mtDNA.
Another patient was diagnosed with MELAS at Saigata National Hos-
pital, Saigata, Joetsu, Niigata, Japan and died at the age of 17. The
autopsied sample (34 mg) from the liver was maintained at 80 C
and was also heteroplasmic, containing both the wild-type and 66%
np 3243 mutated mtDNA.2.3. 3 0-End splint labeling of tRNA
Total RNA from frozen tissue sections or semiconﬂuent cybrid cells
was extracted using Isogen (Nippon Gene, Toyama, Japan), followed
by deacylation of aminoacyl-tRNAs [9]. Total RNA was ﬁrst incu-
bated at 37 C for 30 min in a reaction mixture containing 50 mM
HEPES–KOH (pH 7.5), 10 mM MgCl2, 5 mM DTT, and T4 polynu-
cleotide kinase for dephosphorylation of the 3 0-end of the tRNAs.
Subsequently, 3 0-end CCA repair of tRNAs was performed at 37 C
for 1 h with recombinant human mitochondrial CCA-adding enzyme
[22] in the presence of 1 mM ATP, 1 mM CTP, and 100 mM KCl.
Then, the desired tRNAs were speciﬁcally labeled at their 3 0 termini
by the splint labeling technique [23]. Brieﬂy, total RNA mixed with
20 pmol oligonucleotide probe was incubated at 75 C for 2 min and
then cooled to 37 C for annealing in 50 mM Tris–HCl (pH 7.5),
50 mM NaCl, 1 mM DTT and 0.5 mM EDTA. The probes used were
5 0-GTGGTCACTGTAAAGAGGTGTTGG-3 0 for tRNALys, 5 0-
GTGGTGTTAAGAAGAGGAATTGAACC-3 0 for tRNA-
Leu(UUR), 5 0-GTGGTATTCTCGCACGGACTACAA CC-3 0 for
tRNAGlu, and 5 0-GTGGCTAGGACTATGAGAATCGAACC-3 0 for
tRNAGln. After annealing, 10 mM MgCl2, 1.11 MBq [a-
32P]dCTP
and 10 U of Sequenase (Amersham Pharmacia Biotech, Piscataway,
NJ) were added to the mixture and the reaction was incubated at
37 C for 30 min. The 32P-labeled tRNA was separated by electropho-
resis in a 7 M urea-polyacrylamide gel and then eluted from the gel.
2.4. Sequencing of tRNA
The labeled tRNA was puriﬁed by gel electrophoresis and sequenced
as described previously [9] according to the methods of Donis-Keller
[24]. The gel was exposed on an imaging plate and the radio active
bands were visualized using a BAS5000 bioimaging analyzer (Fuji
Film, Tokyo, Japan).
2.5. APM gel electrophoresis and Northern blotting for the detection of
the thiouridine modiﬁcation
Total RNA containing 3 0-end splint labeled tRNALys, tRNAGlu, or
tRNAGln was electrophoresed in a 10% polyacrylamide gel containing
0.016 mg/mL [(N-acryloylamino)phenyl]mercuric chloride (APM) as
described previously [25–27]. This method was originally developed
by Igloi [28]. Radioactive bands were detected with a BAS5000 bioi-
maging analyzer (Fuji Film).3. Results
3.1. Wobble modiﬁcation deﬁciency in mutant mt tRNAs from
cybrid cells with diﬀerent nuclear backgrounds
The mutant mt tRNALeu(UUR) was isolated by the solid
phase DNA probe method [26,29] from a large scale culture
of A549 lung carcinoma cybrid cells bearing 99% mtDNA with
the A3243G mutation. The puriﬁed tRNA was 5 0-end labeled
and subjected to enzymatic sequencing [24]. As expected, the
mutant mt tRNALeu(UUR) contained a G at position 3243
(Fig. 2, upper panel). In the anticodon region of the wild-type
mt tRNALeu(UUR) (Fig. 2, lower panel), the band at the wobble
position in the alkaline ladder was slightly up-shifted due to
the taurine-modiﬁcation. In addition, no band was observed
in the RNasePhyM (A and U-speciﬁc) lane since sm5U34 is
resistant to RNase digestion [9]. However, no shift of the band
corresponding to the wobble position and a clear band of
RNasePhyM digestion could be observed in the mutant mt
tRNALeu(UUR). This result demonstrates that the wobble base
is an unmodiﬁed uridine. We also analyzed 143B osteosarcoma
cybrid lines with mutant mt tRNALeu(UUR) bearing the
A3243G mutation and found no modiﬁcation of the wobble
base as observed in the mutant tRNA from the A549 lung car-
cinoma cybrid cells (see Supplementary Information). Further-
more, we analyzed the mutant mt tRNALys bearing the
A8344G mutation from 143B cybrid lines and found that the
Fig. 2. Sequence ladders obtained by the Donis-Keller method [24] for
5 0-end labeled wild-type and A3243G mutant tRNALeu(UUR) from
A549 lung carcinoma cybrid cells. Ladders from the regions around
the point mutation (upper panel) and anticodon loop (lower panel) are
shown. E, Al, T1, U2, PM, and CL3 indicate no treatment, and
treatments by alkali, RNase T1 (speciﬁc for G), RNase U2 (for A > G),
RNase PhyM (for A and U), or RNase CL3 (for C), respectively.
Arrowheads show the position of the MELAS 3243 mutation in the
upper panel. In the lower panel, arrows indicate the bands at
the wobble position. The wild-type tRNA shows an up-shifted band
in the alkaline ladder and no band in RNase PhyM lane due to the
taurine modiﬁcation (sm5U), whereas the mutant tRNA shows a
normal ladder in the alkali lane and clear band of RNasePhyM
digestion corresponding to unmodiﬁed uridine (U).
Fig. 3. MELAS patient-derived tRNALeu(UUR) sequencing was com-
pared to the wild-type tRNALeu(UUR). Not only RNases T1 but also U2
and PhyM gave bands at the 3243 mutation point in the patient tRNA
(arrowhead), conﬁrming the coexistence of the mutant and wild-type
tRNALeu(UUR). The wobble position is indicated by dots. The alkali
ladders around the anticodon loop are highlighted in the lower panel
(left) and a densitometric analysis is shown (right). tRNA numbering
was according to the usual method described in the literature [30].
Unusual up-shifting of alkali bands was observed at position 33 of the
wild-type tRNALeu(UUR) because of the wobble modiﬁcation. Addi-
tionally, the AI ladders of the wild-type tRNALeu(UUR) gives clear
bands, whereas those of patient-derived tRNA is smeared at positions
31–33, suggesting the coexistence of unmodiﬁed and modiﬁed uridines
at position 34 (wobble position).
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tion). Together with our previous results using HeLa cybrid
cells [9,10], these data indicate that the wobble modiﬁcation
deﬁciency of the mutant tRNAs from MELAS 3243 and
MERRF 8344 mutations is a universal phenomenon and does
not depend on the nuclear background of the cybrid cell lines.
3.2. Wobble modiﬁcation deﬁciency of mutant mt tRNALeu(UUR)
in MELAS patient tissue
Since a limited amount of patient tissues were available, di-
rect isolation of the mutant mt tRNA for nucleotide modiﬁca-
tion analysis was impractical. Speciﬁc labeling of the mutant
tRNA was achieved instead using the 3 0-end splint labeling
technique [23]. This approach to labeling the tRNAs allowed
us to work directly with unfractionated total RNA from a lim-
ited amount of patient tissue.
A liver autopsy specimen of a MELAS patient was hetero-
plasmic and contained both the wild-type mtDNA and 66%
np 3243 mutated mtDNA. Ninety micrograms total RNA
was isolated from 34 mg tissue. The mutant tRNALeu(UUR)
was 3 0-end labeled by the splint labeling technique (see Section
2). The labeled tRNA was subjected to enzymatic RNA
sequencing [24] and produced bands not only in the presence
of RNase T1 (speciﬁc for G), but also when treated with
RNase U2 (for A > G) and RNase PhyM (Fig. 3, upper panel),
indicating the coexistence of the mutant and the wild-type
tRNALeu(UUR).
In the anticodon region of the alkaline-treated ladders (Fig.
3), a band at the wobble position (position 34, according to thetRNA numbering system [30]) in the wild-type tRNA was up-
shifted due to the taurine-modiﬁcation as shown in Fig. 2. In
contrast, the wobble position from the MELAS patients tissue
reproducibly showed an irregular band pattern between posi-
tions 31 and 33 (Fig. 3, lower panel) and was clearly diﬀerent
from the ladder pattern produced by the wild-type tRNA. The
fact that tRNALeu(UUR) from the patients tissue is a mixture of
the wild-type and the mutant tRNALeu(UUR) (A3243G), and
that the latter has been shown to lack the wobble modiﬁcation
in three diﬀerent nuclear background cybrids (this study and
[9]), suggests that this irregular band pattern in the mutant is
caused by the coexistence of RNA fragment containing
unmodiﬁed U from the tRNALeu(UUR)(A3243G) and fragment
containing sm5U from the wild-type tRNALeu(UUR). This band
pattern in the alkaline ladder was also observed in mutant
tRNALeu(UUR) obtained from a heteroplasmic HeLa cybrid
cell bearing 50% of the A3243G mutation (data not shown).
We could not observe a clear band after RNase PhyM diges-
tion of the mutant mt tRNALeu(UUR) due to the heteroplasmic
A3243G mutation (66%) and low labeling eﬃciency of the mu-
tant tRNA from the MELAS patient (Fig. 3).
3.3. Wobble modiﬁcation deﬁciency in mutant mt tRNALys from
MERRF patient tissue
We obtained 50 lg total RNA from 15 mg of liver autopsy
tissue from a MERRF patient, whose mutation frequency in
mt DNA was determined to be 76% for mt tRNALys. Total
RNA was used for splint labeling of the 3 0-end of the mt
tRNALys. Sequence analysis revealed that the mutant tRNALys
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np 8344, thereby directly demonstrating the existence of the
mutant tRNA in the mitochondria of the patients tissue
(Fig. 4A). In the anticodon region, the sequence ladders
showed that the wobble position of the patient-derived
tRNALys was sensitive to digestion by RNasePhyM, demon-
strating that the wobble base is an unmodiﬁed uridine (Fig.
4A). In contrast, the same position of the wild-type tRNALys
is resistant to this RNase due to the sm5s2U-modiﬁcation
(Fig. 4A). This result is consistent with our previous observa-
tions in cybrid cells [10].
To conﬁrm the absence of the wobble modiﬁcation in the
mutant tRNALys from the MERRF patients tissue, we em-
ployed APM ([(N-acryloylamino)phenyl] mercuric chloride)
gel electrophoresis to separate the mutant tRNA from the
wild-type tRNA containing the 2-thio modiﬁcation of sm5U
[25–28]. In this analysis, the electrophoretic mobility of the ma-
jor portion of tRNAs containing the thiolated nucleotide is sig-Fig. 4. (A) RNA sequence ladders from 3 0-end labeled wild-type and
MERRF patient-derived tRNALys. The regions around the point
mutation and anticodon loop are shown. Arrowheads show the
position of the MERRF 8344 mutation. Bands corresponding to
unmodiﬁed uridine (U) are present at the wobble position in the
patient-derived tRNALys, whereas resistance against RNase PhyM
digestion was observed at the same position in the wild-type tRNALys
because of the sm5s2U modiﬁcation (arrows). (B) Detection of
thiolated nucleotides in tRNA by APM gel electrophoresis. Total
RNA containing 3 0-end labeled tRNALys derived from the wild-type
cybrid cell (C), the MERRF patient tissue (P), and the 8344 mutant
cybrid cell (M), were separated by APM gel electrophoresis (origin at
top). The retarded, smeared band contains tRNALys with the wobble
modiﬁed sm5s2U, whereas the lower band contains tRNA without the
thiolated uridine and residual amounts of tRNA with the thiolated
uridine. The numbers in parentheses indicate the mutation ratio of
mtDNA in each sample. (C) 3 0-End labeled tRNAGlu and tRNAGln
derived from wild-type cybrid (C) or MERRF patient tissue (P) were
separated by APM gel electrophoresis. Both tRNAGlu and tRNAGln
showed equivalent extents of band retardation between the wild-type
cybrid and the MERRF patient sample, indicating the speciﬁcity of the
wobble modiﬁcation deﬁciency in the mutant tRNALys from the
patient sample.niﬁcantly retarded in the presence of APM, due to a speciﬁc
interaction between the thiocarbonyl group and the mercuric
compound in the gel. As shown in Fig. 4B, the majority of
the wild-type mt tRNALys (C) in the gel is retarded due
to the 2-thio group of the sm5s2U at the wobble position,
whereas the mutant mt tRNALys (M) obtained from MERRF
cybrid cells containing 96% A8344G mutations in mt DNA
showed no retardation in the APM gel since the tRNA lacks
the 2-thio modiﬁcation. In mutant mt tRNALys (P) obtained
from MERRF patients tissue with 76% A8344G mutations
in the mt DNA, a small portion of the tRNA was retarded
in the gel, but most of the tRNA showed normal mobility.
These results provide evidence that the mutant tRNALys in
the patients tissue speciﬁcally lacks the 2-thio modiﬁcation
of sm5s2U at the wobble position. To rule out the possibility
that the wobble modiﬁcation deﬁciency of the patient-derived
mutant tRNALys was caused by decreased activity of the
RNA-modifying enzyme responsible for 2-thio modiﬁcation
of sm5s2U, we veriﬁed 2-thio modiﬁcation of other mt tRNAs
that normally have a sm5s2U [8] using APM gel analysis. As
shown in Fig. 4C, mt tRNAs for Glu and Gln in the total
RNA from the MERRF patient tissue showed signiﬁcant
retardation, similar to that of mt tRNAs from wild-type cells,
suggesting that the absence of the wobble modiﬁcation in mt
tRNALys was the direct result of a pathogenic point mutation
and not a change in RNA-modifying enzyme activity. These
results demonstrate that mt tRNALys carrying the A8344G
mutation lacks the sm5s2U modiﬁcation at the wobble position
in patient tissues.4. Discussion
Since the behavior of mtDNA often depends upon the nucle-
ar background in cybrids [17,18], it is substantial to conﬁrm
that the modiﬁcation deﬁciency in mutant mt tRNAs is due
to the mutations even under the diﬀerent nuclear backgrounds
and that the deﬁciency is not speciﬁc in cybrids. We here de-
scribe a wobble modiﬁcation deﬁciency in the mutant mt
tRNALeu(UUR) (A3243G) from three diﬀerent nuclear back-
ground cybrids, and in the mutant mt tRNALys (A8344G)
from two diﬀerent nuclear background cybrids (this study
and [9,10]). The wobble modiﬁcation deﬁciency in the mutant
tRNAs from MELAS and MERRF cybrid cells has been
ﬁrmly established.
The A3243G and A8344G mutations work as a negative
determinant for the biosynthesis of sm5U in tRNALeu(UUR)
and sm5s2U in tRNALys, respectively. This indicates that
the RNA-modifying enzyme responsible for the 5-taurinom-
ethyl group, which has not been identiﬁed, is a class of en-
zyme that recognizes the whole tertiary structure of tRNA,
because both the np 3243 and 8344 are far from the wobble
position (Fig. 1).
Studies using cultured cells have consistently demonstrated
the wobble modiﬁcation deﬁciency, but conﬁrmation that the
same phenomenon occurs in patient tissues has not been re-
ported previously. By overcoming the diﬃculty in sequencing
tRNAs from small amounts of tissue, we were able to show
that patient tissues lacked the wobble modiﬁcation in the mu-
tant tRNALeu(UUR) (A3243G) and tRNALys (A8344G). This
ﬁnding provides the ﬁrst link between our biochemical obser-
vations and clinical analysis, which is a necessary ﬁrst step in
2952 T. Yasukawa et al. / FEBS Letters 579 (2005) 2948–2952the development of diagnostic procedures and possible thera-
peutic measures.
Mitochondrial dysfunctions such as MELAS or MERRF
could have multiple causes, including impaired termination of
transcription, decreased RNase P processing, decreased tRNA
stability, aminoacylation, or abnormal conformations [31,32],
which would lead to decreased steady-state levels of the normal
aminoacylated tRNAs and result in reduced mitochondrial
protein synthesis. However, particularly in the case of MELAS,
the reduced mitochondrial protein synthesis in cells with these
pathogenic mutations cannot explain the decreased respiratory
activity or oxygen consumption, since the extent of the reduc-
tion in protein synthesis does not parallel the defective enzy-
matic activity [7,20,33,34]. Thus, reduced protein synthesis
caused by quantitative defects of the mutant tRNAs does not
appear to be the direct cause of the clinical symptoms presented
by MELAS. Qualitative defects are likely to arise from the
wobble modiﬁcation deﬁciency, since the mutant tRNAs lack-
ing wobble modiﬁcations show codon-speciﬁc decoding disor-
ders [15]. This suggests that the lack of wobble modiﬁcation
is a major causative factor of these mitochondrial diseases.
In conclusion, the present study excluded the possibility that
the modiﬁcation deﬁciency of the wobble position is limited to
HeLa cybrids and conﬁrmed that the wobble modiﬁcation deﬁ-
ciency occurs in patient tissues.
Acknowledgments:We thank Dr. A. Chomyn and Dr. G. Attardi (Cal-
Tech, Pasadena, CA) for providing 143B osteosarcoma cybrid clones,
and T. Nagaike (University of Tokyo) for the recombinant CCA-
adding enzyme. This work was supported by grants-in-aid for scientiﬁc
research on priority areas from the Ministry of Education, Science,
Sports, and Culture of Japan (to T.S. and K.W.), by a JSPS Fellowship
for Japanese Junior Scientists (to Y.K.), by a grant from the New En-
ergy and Industrial Technology Development Organization (NEDO)
(to T.S.) and by the Human Frontier Science Program (grant
RG0349) (to T.S.). I.J.H. and H.T.J. are supported, respectively, by
the UK Medical Research Council and the Academy of Finland.Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/j.febslet.2005.
04.038.References
[1] Schon, E.A., Bonilla, E. and DiMauro, S. (1997) J. Bioenerg.
Biomembr. 29, 131–149.
[2] Goto, Y., Nonaka, I. and Horai, S. (1990) Nature 348, 651–653.
[3] Kobayashi, Y., Momoi, M.Y., Tominaga, K., Momoi, T., Nihei,
K., Yanagisawa, M., Kagawa, Y. and Ohta, S. (1990) Biochem.
Biophys. Res. Commun. 173, 816–822.
[4] Shoﬀner, J.M., Lott, M.T., Lezza, A.M., Seibel, P., Ballinger,
S.W. and Wallace, D.C. (1990) Cell 61, 931–937.
[5] King, M.P. and Attardi, G. (1989) Science 246, 500–503.[6] Hayashi, J., Ohta, S., Kikuchi, A., Takemitsu, M., Goto, Y. and
Nonaka, I. (1991) Proc. Natl. Acad. Sci. USA 88, 10614–10618.
[7] Dunbar, D.R., Moonie, P.A., Zeviani, M. and Holt, I.J. (1996)
Hum. Mol. Genet. 5, 123–129.
[8] Suzuki, T., Suzuki, T., Wada, T., Saigo, K. and Watanabe, K.
(2002) EMBO J. 21, 6581–6589.
[9] Yasukawa, T., Suzuki, T., Suzuki, T., Ueda, T., Ohta, S. and
Watanabe, K. (2000) J. Biol. Chem. 275, 4251–4257.
[10] Yasukawa, T., Suzuki, T., Ishii, N., Ueda, T., Ohta, S. and
Watanabe, K. (2000) FEBS Lett. 467, 175–178.
[11] Suzuki, T. (2005) in: (Grosjean, H., Ed.), Topics in Current
Genetics, vol. 12, pp. 24–69, Springer-Verlag, New York.
[12] Bjork, G.R. (1995) in: tRNA: Structure, Biosynthesis and
Function (Soll, D. and Rajbandary, U.L., Eds.), pp. 165–205,
ASM press, Washington, DC.
[13] Yokoyama, S. and Nishimura, S. (1995) in: tRNA: Structure,
Biosynthesis and Function (Soll, D. and Rajbandary, U.L., Eds.),
pp. 207–224, ASM press, Washington, DC.
[14] Yasukawa, T., Suzuki, T., Ishii, N., Ohta, S. and Watanabe, K.
(2001) EMBO J. 20, 4794–4802.
[15] Kirino, Y., Yasukawa, T., Ohta, S., Akira, S., Ishihara, K.,
Watanabe, K. and Suzuki, T. (2004) Proc. Natl. Acad. Sci. USA
101, 15070–15075.
[16] Kirino, Y. and Suzuki, T. (2005) RNA Biol. 1 (in press).
[17] Holt, I.J., Dunbar, D.R. and Jacobs, H.T. (1997) Hum. Mol.
Genet. 6, 1251–1260.
[18] Dunbar, D.R., Moonie, P.A., Jacobs, H.T. and Holt, I.J. (1995)
Proc. Natl. Acad. Sci. USA 92, 6562–6566.
[19] Chomyn, A., Meola, G., Bresolin, N., Lai, S.T., Scarlato, G. and
Attardi, G. (1991) Mol. Cell Biol. 11, 2236–2244.
[20] Chomyn, A., et al. (1992) Proc. Natl. Acad. Sci. USA 89, 4221–
4225.
[21] Fukuhara, N., Tokiguchi, S., Shirakawa, K. and Tsubaki, T.
(1980) J. Neurol. Sci. 47, 117–133.
[22] Nagaike, T., Suzuki, T., Tomari, Y., Takemoto-Hori, C., Neg-
ayama, F., Watanabe, K. and Ueda, T. (2001) J. Biol. Chem. 276,
40041–40049.
[23] Schneider, A., McNally, K.P. and Agabian, N. (1994) Nucleic
Acids Res. 22, 3699–3705.
[24] Donis-Keller, H. (1980) Nucleic Acids Res. 8, 3133–3142.
[25] Shigi, N., Suzuki, T., Tamakoshi, M., Oshima, T. and Watanabe,
K. (2002) J. Biol. Chem. 277, 39128–39135.
[26] Kaneko, T., Suzuki, T., Kapushoc, S.T., Rubio, M.A., Ghazvini,
J., Watanabe, K., Simpson, L. and Suzuki, T. (2003) EMBO J. 22,
657–667.
[27] Umeda, N., Suzuki, T., Yukawa, M., Ohya, Y., Shindo, H.,
Watanabe, K. and Suzuki, T. (2005) J. Biol. Chem. 280, 1613–
1624.
[28] Igloi, G.L. (1988) Biochemistry 27, 3842–3849.
[29] Wakita, K., Watanabe, Y., Yokogawa, T., Kumazawa, Y.,
Nakamura, S., Ueda, T., Watanabe, K. and Nishikawa, K.
(1994) Nucleic Acids Res. 22, 347–353.
[30] Sprinzl, M., Horn, C., Brown, M., Ioudovitch, A. and Steinberg,
S. (1998) Nucleic Acids Res. 26, 148–153.
[31] Jacobs, H.T. (2003) Hum. Mol. Genet. 12 (Spec No 2), R293–
R301.
[32] Florentz, C., Sohm, B., Tryoen-Toth, P., Putz, J. and Sissler, M.
(2003) Cell Mol. Life Sci. 60, 1356–1375.
[33] Hayashi, J., Ohta, S., Takai, D., Miyabayashi, S., Sakuta, R.,
Goto, Y. and Nonaka, I. (1993) Biochem. Biophys. Res.
Commun. 197, 1049–1055.
[34] Flierl, A., Reichmann, H. and Seibel, P. (1997) J. Biol. Chem. 272,
27189–27196.
[35] Helm, M., Florentz, C., Chomyn, A. and Attardi, G. (1999)
Nucleic Acids Res. 27, 756–763.
